No — this is one of the most common misconceptions in cell biology. Serum provides a complex, biologically relevant environment that many cells — especially primary cells — genuinely require. Serum-free media can reduce variability and improve regulatory compliance, but they often require optimisation per cell type and can alter phenotype or assay sensitivity. The correct question is not "serum vs. serum-free" but "which supplement gives the most consistent, biologically appropriate, and application-suitable result for my specific cell type and goal?"

For most established human cell lines — yes. Human AB serum and hPL are biologically equivalent to FBS in terms of growth support, and for human cells they are often superior. Start with a direct switch at the same concentration (10% hPL or human AB serum replacing 10% FBS). If viability and doubling time are maintained after 2–3 passages, adaptation is successful. A stepwise transition is rarely necessary for this specific switch.

hPL is produced by freeze-thaw lysis of human platelets, releasing a concentrated pool of growth factors including PDGF, TGF-β, bFGF, VEGF, EGF and IGF-1. For human cell types — particularly MSCs, fibroblasts and other primary human cells — hPL at 5% is frequently superior to FBS at 10% in terms of proliferation rate and maintenance of phenotypic characteristics. It is xeno-free, human-derived, and GMP-grade formulations are available for ATMP manufacturing. Its main limitations are: requires heparin addition to prevent clotting (or use heparin-free/fibrinogen-depleted hPL), lot-to-lot variability remains (though lower than FBS with large pooling), and it is not suitable for hybridoma culture (introduces human IgG that co-purifies with murine mAb).

Transferrin is the primary iron delivery protein in serum. It binds iron in circulation and delivers it to cells via transferrin receptor-mediated endocytosis — triggering receptor recycling and intracellular iron release. Without a transferrin source in serum-free medium, cells become iron-limited within 48–72 hours and show reduced proliferation, mitochondrial dysfunction, and eventual apoptosis. OsrhTF (rice-expressed, ≥99% purity) is used at 5–10 µg/mL in serum-free medium to replace this function. It is animal-free, defined, and fully recombinant — compatible with GMP and ATMP applications.

For established cancer cell lines switching from FBS to human serum or hPL: often 1–3 passages (1–2 weeks). For stepwise transition to chemically defined serum-free medium: typically 7–10 passages (3–6 weeks) using 25% incremental reduction per 2 passages. For suspension adaptation of adherent lines (e.g. HEK293 for bioreactor production): 4–8 weeks including suspension adaptation and performance validation. Always allow 3–5 additional passages after the final switch before using cells for experiments, to ensure phenotypic stability.

Yes — for sensitive adherent cell types (primary cells, iPSC-derived cells, some hybridomas during adaptation), adding Y-27632 (ROCK inhibitor, 10 µM) during the 48–72 h immediately after each medium change significantly reduces anoikis (detachment-induced apoptosis). This is particularly useful at the 50% and 75% serum-free stages where anoikis risk is highest. Remove Y-27632 after the adaptation period — do not use it permanently as it can alter cytoskeletal organisation and migration phenotype.

Yes — rHSA (recombinant human serum albumin) can replace BSA in most serum-free cell culture applications where albumin is used as a carrier, stabiliser or fatty acid source. rHSA is human-sequence albumin expressed in rice, is animal-free, and has higher lot-to-lot consistency than BSA (which is bovine-derived). For GMP and xeno-free applications, rHSA is the preferred choice. For cost-sensitive non-GMP research applications, BSA remains widely used due to price advantage.

Post-mitotic neurons and terminally differentiated cells typically cannot be maintained serum-free without highly specialised neuronal media (e.g. Neurobasal + B27). Approximately 3–5% of hybridoma lines fail serum-free adaptation regardless of protocol — use FBS Ultra Low IgG as the alternative in these cases. Highly serum-dependent primary cells (some hepatocyte preparations, some smooth muscle cells) may require serum at low concentrations (<2%) permanently. If a cell type has no published serum-free protocol in PubMed, expect significant optimisation time before achieving equivalent performance.